This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
| less than a minute read

FDA approve video game as a clinical treatment

A really inspiring development in the digital therapeutics sphere with the FDA approving a video based game as a prescription treatment for ADHD.  It will be really interesting to see, especially in a post-Covid world, how tech solutions are able to help us in more diverse ways - and how both big tech and more traditional healthcare companies will adjust and potentially collaborate. 

Akili today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for EndeavorRxTM (AKL-T01) as a prescription treatment for children with attention deficit hyperactivity disorder (ADHD). Delivered through a captivating video game experience, EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue.

Latest Insights

post featured image